Director/PDMR Shareholding

October 01, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 1 October 2018 that on 27 and 28 September 2018, it purchased 81 and 910,608 Ordinary Shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,317,088 equivalent to 20.43% of Proteome Sciences' total issued share capital.

Back to News